DRRX Stock - DURECT Corporation
Unlock GoAI Insights for DRRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.03M | $8.55M | $19.28M | $13.98M | $30.11M |
| Gross Profit | $1.95M | $6.83M | $17.70M | $12.02M | $28.70M |
| Gross Margin | 96.2% | 79.9% | 91.8% | 86.0% | 95.3% |
| Operating Income | $-18,912,000 | $-36,884,000 | $-35,082,000 | $-34,273,000 | $-12,615,000 |
| Net Income | $-8,324,000 | $-27,624,000 | $-35,333,000 | $-36,265,000 | $-13,427,000 |
| Net Margin | -409.8% | -323.2% | -183.2% | -259.5% | -44.6% |
| EPS | $-0.27 | $-1.22 | $-1.55 | $-1.61 | $-0.67 |
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Visit WebsiteEarnings History & Surprises
DRRXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 12, 2025 | $-0.13 | $-0.07 | +46.2% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.13 | $-0.13 | 0.0% | = MET |
Q1 2025 | Mar 26, 2025 | $0.06 | $-0.06 | -200.0% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.17 | $-0.14 | +17.6% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.17 | $-0.12 | +29.4% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.22 | $-0.25 | -13.6% | ✗ MISS |
Q1 2024 | Mar 27, 2024 | $-0.36 | $-0.27 | +25.0% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.41 | $-0.40 | +2.4% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.51 | $-0.42 | +17.6% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.53 | $-0.47 | +11.3% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $-0.55 | $-0.46 | +16.4% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.10 | $-0.10 | 0.0% | = MET |
Q3 2022 | Aug 4, 2022 | $-0.47 | $-0.50 | -6.4% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.53 | $-0.50 | +5.7% | ✓ BEAT |
Q1 2022 | Mar 7, 2022 | $-0.47 | $-0.30 | +36.2% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-0.47 | $-0.40 | +14.9% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $-0.42 | $-0.40 | +4.8% | ✓ BEAT |
Q2 2021 | May 4, 2021 | $-0.44 | $-0.50 | -13.6% | ✗ MISS |
Q1 2021 | Mar 4, 2021 | $-0.30 | $-0.40 | -33.3% | ✗ MISS |
Q4 2020 | Nov 2, 2020 | $-0.43 | $-0.50 | -16.3% | ✗ MISS |
Frequently Asked Questions about DRRX
What is DRRX's current stock price?
What is the analyst price target for DRRX?
What sector is DURECT Corporation in?
What is DRRX's market cap?
Does DRRX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DRRX for comparison